Clinical Trial Update: A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) [Phase 2]

View source ↗

Summary

A Phase 2 study to evaluate pharmacokinetics, safety, tolerability, immunogenicity and pharmacodynamic effects of subcutaneous ocrelizumab in children and adole…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 2 | Status: NOT_YET_RECRUITING